Verified Panel · Retention-Built · Multi-Timepoint
Rare disease is a
longitudinal problem
Diagnostic delay, disease progression, treatment switching, and the long-term effects of orphan therapies all unfold over years rather than weeks. A single cross-sectional data point — however well-designed — can only tell part of the story.
MedPanel’s observational and longitudinal research practice is built to follow rare disease patients, caregivers, and physicians over time, using a verified panel and rare disease–specific retention strategies to produce the durable, multi-timepoint evidence that regulatory bodies, payers, and clinical teams increasingly require.
Natural history · Durability · Caregiver trajectory
Paced to disease progression, not defaults
CAWI · IDIs · Symptom diaries
Upfront plus periodic re-confirmation
Why Rare Disease Evidence Needs a Time Dimension
Cross-sectional research answers “what is true right now.” Many of the most important questions in rare disease are instead about trajectory — how burden, durability, and caregiving shift over years.
- Natural history characterization is the most fundamental application. For many rare and ultra-rare conditions, the natural history of disease progression is incompletely documented in the literature, particularly for genetically defined subtypes only recently distinguished from broader diagnostic categories. Longitudinal observational research with a verified patient panel can establish progression patterns that inform clinical trial endpoint selection, sample size planning, and external comparator arms — an increasingly important application as single-arm trials with external control data become more common in orphan drug development.
- Treatment durability and real-world effectiveness tracking is a second core application. Clinical trial data captures efficacy over a defined trial period; longitudinal observational research captures what happens after — whether benefit is maintained, whether adherence holds, and whether the burden reduction observed in controlled settings translates to lived experience over an extended period.
- Caregiver and family trajectory research extends the same logic. Caregiver burden can shift substantially across a treatment journey — often decreasing with effective therapy but sometimes shifting in character rather than magnitude as patients survive longer with more complex ongoing care needs.
Designing for Retention in Small Populations
Longitudinal research lives or dies on retention — and retention is harder in rare disease than almost any other context, because the population is too small to absorb significant attrition without compromising statistical power.
Realistic timepoint planning
Rather than defaulting to standard intervals borrowed from common-disease longitudinal research, MedPanel works with sponsors to determine timepoint frequency based on the actual pace of disease progression or treatment response for the specific condition — quarterly assessment for slowly progressive conditions, more frequent touchpoints around key treatment milestones such as therapy initiation or dose escalation.
Participant burden management
Burden management is built into the protocol from study design forward, not bolted on after early dropout signals appear. This includes minimizing assessment length at each timepoint, varying data collection modality across timepoints where appropriate (brief check-in surveys alternating with deeper periodic assessments), and maintaining consistent point-of-contact relationships between participants and the MedPanel research team — a continuity that matters disproportionately to rare disease families who have often grown wary of research engagements that feel transactional or anonymous.
Mixed-mode data collection
Mixed-mode data collection allows longitudinal protocols to combine structured CAWI surveys, periodic in-depth interviews, and passive or semi-passive data sources (such as patient-reported symptom diaries) within a single study architecture — capturing both the quantifiable trajectory and the qualitative texture of disease experience over time.
Observational Research Without an Interventional Arm
Not all observational research is longitudinal in the multi-year sense — MedPanel also supports point-in-time studies that characterize a population without extended follow-up.
MedPanel supports observational studies designed to characterize a patient population at a defined point or short window — disease burden snapshots, treatment pattern audits, or real-world utilization studies that inform market access strategy without requiring extended follow-up.
These shorter observational designs are particularly useful for sponsors who need a current, verified picture of how a rare disease is actually being managed in practice — diagnostic pathways being used, treatments being prescribed off-label or under expanded access, and gaps between guideline recommendations and real-world care. Because MedPanel’s panel spans verified patients, caregivers, and treating physicians, observational studies can be designed to triangulate across all three perspectives within the same data collection window.
Global Panel Depth for Sustained Engagement
Longitudinal rare disease research requires a panel relationship that survives well beyond a single study engagement.
MedPanel’s global reach across North America, Europe, Asia-Pacific, and Latin America provides the panel depth needed to absorb expected attrition over a multi-year study while maintaining a sample that remains representative of the target population.
Verification is, if anything, more important in longitudinal research than in single-timepoint studies. A misclassified participant identified at month eighteen of a three-year study represents a substantial loss — not just of that participant’s data, but of analytical continuity for any model depending on a complete time series. MedPanel’s upfront verification process, combined with periodic re-confirmation protocols for extended studies, protects the integrity of longitudinal datasets across their full duration.
For programs requiring institutional oversight across an extended study period, MedPanel’s IRB-ready documentation includes provisions for continuing review, protocol amendments, and the specific consent considerations that apply to long-term participant relationships — distinct from the single-engagement consent architecture used in cross-sectional research.
Build the evidence
Build the Longitudinal Evidence Your Rare Disease Program Needs
Whether you need natural history data to inform trial design, real-world durability evidence post-launch, or a structured observational snapshot of current treatment patterns, MedPanel’s verified panel and rare disease specialists can design a study architecture suited to your evidence timeline.
Natural history data to inform trial design and endpoints
Real-world durability and effectiveness tracking post-launch
Retention-built design with periodic re-confirmation
IRB-ready documentation for continuing review and amendments
Contact MedPanel to discuss your observational or longitudinal research objectives. We will assess panel feasibility for sustained engagement and outline a study design matched to your evidentiary requirements.